Rozlytrek and Xanax

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with entrectinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by entrectinib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. When oral midazolam, a sensitive CYP450 3A4 substrate, was administered with entrectinib 600 mg once daily, midazolam peak plasma concentration (Cmax) decreased by 21% but systemic exposure (AUC) increased by 50%. These results suggest weak inhibition of CYP450 3A4 by entrectinib. MANAGEMENT: Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, lovastatin, macrolide immunosuppressants, midazolam, sildenafil, simvastatin, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever entrectinib is added to or withdrawn from therapy. References "Product Information. Rozlytrek (entrectinib)." Genentech, South San Francisco, CA.

MONITOR: Coadministration with entrectinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is reduced clearance due to inhibition of CYP450 3A4 by entrectinib. The interaction may be particularly important for sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index. When oral midazolam, a sensitive CYP450 3A4 substrate, was administered with entrectinib 600 mg once daily, midazolam peak plasma concentration (Cmax) decreased by 21% but systemic exposure (AUC) increased by 50%. These results suggest weak inhibition of CYP450 3A4 by entrectinib.

MANAGEMENT: Caution may be advisable when entrectinib is used with sensitive CYP450 3A4 substrates or those that demonstrate a narrow therapeutic index (e.g., ergot alkaloids, colchicine, fentanyl, lovastatin, macrolide immunosuppressants, midazolam, sildenafil, simvastatin, triazolam, vardenafil, vinca alkaloids). Dosage adjustments as well as clinical and laboratory monitoring may be appropriate whenever entrectinib is added to or withdrawn from therapy.

Rozlytrek

Generic Name: entrectinib

Brand name: Rozlytrek

Synonyms: n.a.

What is Rozlytrek?

Xanax

Generic Name: alprazolam

Brand name: Niravam, Xanax, Xanax XR, Alprazolam Intensol

Synonyms: n.a.

What is Xanax?